Skip to main content

Advertisement

SpringerLink
Log in

Management of Patients with MYC-Altered Lymphomas

  • B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Patients diagnosed with non-Burkitt high-grade B cell non-Hodgkin lymphomas demonstrating rearrangement in MYC, an oncogene promoting cellular proliferation, frequently do not achieve long-term disease-free survival due to a suboptimal response to standard front-line and salvage therapies. Double-hit lymphomas, harboring rearrangements in MYC as well as BCL2 and/or BCL6, appear to carry a particularly poor prognosis, although patients with this disease appear to achieve better survival outcomes when treated with intensified chemotherapy. Increased expression of MYC protein by immunohistochemistry as well as increased copy number or amplification of MYC may also be adverse pathologic features of non-Burkitt high-grade B cell non-Hodgkin lymphomas, although the benefit of treating these patients with intensified as opposed to standard dose chemotherapy remains unclear. Recognition and proper management of patients with MYC-altered lymphomas is crucial to improving patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(19):3121–7. doi:10.1200/JCO.2005.05.1003.

    Article  CAS  Google Scholar 

  2. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91. doi:10.1016/S1470-2045(06)70664-7.

    Article  CAS  PubMed  Google Scholar 

  3. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(27):4184–90. doi:10.1200/JCO.2010.28.1618.

    Article  Google Scholar 

  4. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62. doi:10.1182/blood-2012-06-436725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(10):1342–8. doi:10.1200/JCO.2010.30.2596.

    Article  Google Scholar 

  6. Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012;118(6):1566–73. doi:10.1002/cncr.26433. Large case series of BCLU patients reproting outcomes based on MYC -R status.

  7. Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, Smith LM, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol. 2013;162(1):40–9. doi:10.1111/bjh.12343.

    Article  CAS  PubMed  Google Scholar 

  8. Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood. 1991;77(5):1057–63.

    CAS  PubMed  Google Scholar 

  9. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3152–62.

    CAS  PubMed  Google Scholar 

  10. Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma. 2004;45(3):519–28.

    Article  CAS  PubMed  Google Scholar 

  11. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30. doi:10.1056/NEJMoa055351.

    Article  CAS  PubMed  Google Scholar 

  12. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–7. doi:10.1182/blood-2009-05-220095.

    Article  CAS  PubMed  Google Scholar 

  13. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(20):3360–5. doi:10.1200/JCO.2009.26.3947. Large case series demonstrating poor prognosis of patients with MYC -R DLBCL treated with R-CHOP.

  14. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2008;22(12):2226–9. doi:10.1038/leu.2008.230.

    Article  CAS  Google Scholar 

  15. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–90. doi:10.1038/nrc2231.

    Article  CAS  PubMed  Google Scholar 

  16. Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–64. doi:10.1016/j.semcancer.2006.07.014.

    Article  CAS  PubMed  Google Scholar 

  17. Ngo CV, Gee M, Akhtar N, Yu D, Volpert O, Auerbach R, et al. An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ. 2000;11(4):201–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Meyer N, Kim SS, Penn LZ. The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol. 2006;16(4):275–87. doi:10.1016/j.semcancer.2006.07.011.

    Article  CAS  PubMed  Google Scholar 

  19. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341–6. doi:10.1038/35085588.

    Article  CAS  PubMed  Google Scholar 

  20. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–35. doi:10.3324/haematol.2013.091827. Comparison of patholgoic features and outcomes in patients with MYC -R lymphomas, including SHL and DHL.

  21. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–31. doi:10.1182/blood-2010-09-297879.

    Article  CAS  PubMed  Google Scholar 

  22. Setoodeh R, Schwartz S, Papenhausen P, Zhang L, Sagatys EM, Moscinski LC, et al. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int J Clin Exp Pathol. 2013;6(2):155–67.

    PubMed  PubMed Central  Google Scholar 

  23. Reddy K, Ansari-Lari M, Dipasquale B. Blastic mantle cell lymphoma with a Burkitt translocation. Leuk Lymphoma. 2008;49(4):740–50. doi:10.1080/10428190701852024.

    Article  CAS  PubMed  Google Scholar 

  24. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–9. doi:10.1182/blood-2009-03-212191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145–56. doi:10.1038/modpathol.2011.147.

    Article  CAS  PubMed  Google Scholar 

  26. Pedersen MO, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma—a single centre’s experience. Eur J Haematol. 2012;89(1):63–71. doi:10.1111/j.1600-0609.2012.01787.x.

    Article  PubMed  Google Scholar 

  27. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40. doi:10.1097/PAS.0b013e3181cd3aeb.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015. doi:10.1182/blood-2015-05-647602.

    PubMed  Google Scholar 

  29. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–63. doi:10.1182/blood-2012-06-435842.

    Article  CAS  PubMed  Google Scholar 

  30. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(28):3460–7. doi:10.1200/JCO.2011.41.4342. Large case series demonstrating poor prognosis of DEL DLBCL.

    Article  CAS  Google Scholar 

  31. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(28):3452–9. doi:10.1200/JCO.2011.41.0985. Large case series demonstrating poor prognosis of DEL DLBCL.

    Article  CAS  Google Scholar 

  32. Turakhia SK, Hill BT, Dufresne SD, Nakashima MO, Cotta CV. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. Am J Clin Pathol. 2014;142(3):339–46. doi:10.1309/AJCPBWVHTF7RRSA4.

    Article  PubMed  Google Scholar 

  33. Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323–32. doi:10.1097/PAS.0b013e31826cebad.

    Article  PubMed  Google Scholar 

  34. Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases. Am J Surg Pathol. 2015;39(8):1132–9. doi:10.1097/PAS.0000000000000434.

    Article  PubMed  Google Scholar 

  35. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901. doi:10.1111/bjh.12982.

    Article  CAS  PubMed  Google Scholar 

  36. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, et al. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer. 2015. doi:10.1002/cncr.29781.

    PubMed  Google Scholar 

  37. Caponetti GC, Dave BJ, Perry AM, Smith LM, Jain S, Meyer PN et al. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. Leuk Lymphoma. 2015:1–8. doi:10.3109/10428194.2015.1034699

  38. Landsburg DJ, Falkiewicz MK, Morrissette JJD, Schrank-Hacker AM, Dwivedy Nasta S, Svoboda J, et al. Patients with “single-hit” but not MYC-amplified non-Burkitt high-grade B cell non-Hodgkin lymphomas experience poor survival outcomes and may benefit from intensive induction therapy. Blood. 2015;126(23):2696.

    Google Scholar 

  39. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18(3):219–28. doi:10.1097/PAP.0b013e3182169948.

    Article  PubMed  Google Scholar 

  40. Lin P, Medeiros LJ. The impact of MYC rearrangements and “double hit” abnormalities in diffuse large B-cell lymphoma. Curr Hematol Malig Rep. 2013;8(3):243–52. doi:10.1007/s11899-013-0169-y.

    Article  PubMed  Google Scholar 

  41. Braziel RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C, et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood. 2001;97(12):3713–20.

    Article  CAS  PubMed  Google Scholar 

  42. Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2009;23(2):225–34. doi:10.1038/leu.2008.281.

    Article  CAS  Google Scholar 

  43. Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2015;29(7):1564–70. doi:10.1038/leu.2015.43.

    CAS  Google Scholar 

  44. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013;98(10):1554–62. doi:10.3324/haematol.2013.086173. Case series describing outcomes in patients with various forms of MYC -altered lymphoma, specifically MYC -E lymphomas.

  45. Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014. doi:10.1111/bjh.12763.

    Google Scholar 

  46. Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205–17. doi:10.1111/j.1365-2559.2008.03076.x.

    Article  CAS  PubMed  Google Scholar 

  47. Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, Mason DY, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn : JMD. 2006;8(2):141–51. doi:10.2353/jmoldx.2006.050083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Agarwal R, Lade S, Liew D, Rogers TM, Byrne D, Feleppa F, et al. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases. J Clin Pathol. 2015. doi:10.1136/jclinpath-2015-203002.

    PubMed  Google Scholar 

  49. Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, Amouroux I, et al. Non-Hodgkin’s lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma. 2006;47(9):1885–93. doi:10.1080/10428190600687547.

    Article  CAS  PubMed  Google Scholar 

  50. Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, et al. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677–85. doi:10.1002/cncr.28642.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Dunleavy K, Fanale M, LaCasce A, Noy A, Caimi P, Parekh S, et al. Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. Blood. 2014;124(21):395.

    Google Scholar 

  52. Pedersen MO, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42–8. doi:10.1111/ejh.12212.

    Article  CAS  PubMed  Google Scholar 

  53. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61. doi:10.1182/blood-2014-05-578963. Very large series of DHL patients demonstrating improved progression free sruvival for patients recieveing intensive induction therapy.

    Article  CAS  PubMed  Google Scholar 

  54. Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–14. doi:10.1111/bjh.13463.

    Article  PubMed  Google Scholar 

  55. Li S, Desai P, Lin P, Yin CC, Tang G, Wang XJ, et al. MYC/BCL6 Double Hit Lymphoma (DHL): A Tumor Associated with an Aggressive Clinical Course and Poor Prognosis. Histopathology. 2015. doi:10.1111/his.12884.

    Google Scholar 

  56. Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2015. doi:10.18632/oncotarget.6262.

    Google Scholar 

  57. Li S, Weiss VL, Wang XJ, Desai PA, Hu S, Yin CC, et al. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis. Am J Surg Pathol. 2015. doi:10.1097/PAS.0000000000000542.

    PubMed Central  Google Scholar 

  58. Testoni M, Kwee I, Greiner TC, Montes-Moreno S, Vose J, Chan WC, et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol. 2011;155(2):274–7. doi:10.1111/j.1365-2141.2011.08675.x.

    Article  CAS  PubMed  Google Scholar 

  59. Wang XJ, Medeiros LJ, Lin P, Yin CC, Hu S, Thompson MA, et al. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Am J Surg Pathol. 2015;39(9):1250–8. doi:10.1097/PAS.0000000000000433.

    Article  PubMed  Google Scholar 

  60. Herrera AF, Mei MG, Low L, Merryman RW, Song JY, Paris T, et al. Double expressing (MYC/BCL2) and double-hit diffuse large b-cell lymphomas have inferior survival following autologous stem cell transplantation. Blood. 2015;126(23):522.

    Google Scholar 

  61. Younes A, Berdeja JG, Patel MR, Kelly KR, Flinn IW, Gerecitano JF, et al. Phase 1 trial testing single agent CUDC-907, a novel, oral dual inhibitor of histone deacetylase (HDAC) and PI3K: initial assessment of patients with relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL), including double expressor (DE) lymphoma. Blood. 2015;126(23):257.

    Google Scholar 

  62. Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014;111(26):E2721–30. doi:10.1073/pnas.1406722111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Abramson JS, Blum KA, Flinn IW, Gutierrez M, Goy A, Maris M, et al. BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study. Blood. 2015;126(23):1491.

    Google Scholar 

  64. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013;121(12):2285–8. doi:10.1182/blood-2013-01-475855.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Gerecitano JF, Roberts AW, Seymour JF, Wierda WG, Kahl BS, Pagel JM, et al. A phase 1 study of venetoclax (ABT-199 / GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126(23):254.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abramson Cancer Center, Division of Hematology/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, PCAM 2, South Philadelphia, PA, 19104, USA

    Daniel J. Landsburg

Authors
  1. Daniel J. Landsburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Landsburg.

Ethics declarations

Conflict of Interest

Daniel J. Landsburg reports personal fees from Curis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the topical collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Landsburg, D.J. Management of Patients with MYC-Altered Lymphomas. Curr Hematol Malig Rep 11, 208–217 (2016). https://doi.org/10.1007/s11899-016-0320-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0320-7

Keywords

Search

Navigation